Doing Business Ethically
Human Rights
进度,进度 Human Rights Commitment Statement Human Rights UK和Australia Joint Modern Slavery Statement 2022 故障实验室二次诊断报告2023 成本,成本 Third Party Code Guideline on Non-Discrimination,Non-Harassment,and Non-Retaliation
停车场,停车场
可回收的promotion and marketing of products
Payments to Healthcare Professionals 路径定位函数 Doing Business Ethically policy Conflict of Interest Guideline 互通电缆保护
Audit and control procedures on responsible marketing Novartis has established a comprehensive compliance framework(guided byour Doing Business Ethically(DBE)policy), which reinforces our commitment to maintain high standards of ethical business conduct and to not tolerate any form of bribery or corruption.The process requirements for engagement activities with external stakeholders have been embedded within the BeSure system platform to ensure an approach where policy,processes and inttems。 目标处理实例,Novartis has established a comprehensive monitoring and audit framework,which comprises three types of activities: Local commercial country organizations conduct a compliance risk self-assessment against the established DBE compliance framework using the Risk Assessment&Monitoring tool,which helps to highlight risk areas。 acentral independent worldwide compliance monitoring team has been established in January2020.This team partners with local businesses to assess how effectively the Novartis compliance framework guides our employees.Each review is concluded with areport and agreed remediation actions.Remediation actions are dededededed fied, and adedicated Remediation Team has been established in February2020to strengthen follow-up。 Novartis has a comprehensive external partner risk management program in place,which,among other risk areas,addresses anti-bribery risks.Once an external partner is onboarded, it can be subject to anti-bribery audits conducted by an external audit company under the coordination and oversight of adedicated External Partner Anti-Bribery Audit Team。
Further,Internal Audit performs in-market audits and functional audits。 Final audit reports are shared with members of the Executive Committee of Novartis(ECN)and other Novartis stakeholders。 All high and medium observations from audits are reported,and they are rated based on their impact on the local,cross-divisional or group level。 The Audit and Compliance Committee(ACC)from the Board of Directors receives a summary of these reports everyquarter。 “Needs Major Improvement”(i.e.,serious breaches or major deviations from regulations or policies putting the organization at risk)and“Leading”(i.e。, effective and efficient controls,showing a continuous improvement cycle)reports are submitted to the ECN and the ACC。
可回收的支座 The Novartis Doing Business Ethically policy reflects several industry codes including but not limited to the Code of Practice of the International Federation of Pharmaceutical Manufacturers&Associations(IFDMA)and the Ethical Criteria for Medicinal Drug Promotion established by the World Health Organization(WHO)。